Dermata Therapeutics, Inc.DRMAEarnings & Financial Report
Nasdaq
NextMar 25, 2026
DRMA Q3 2023 Key Financial Metrics
Revenue
$92.8K
Gross Profit
N/A
Operating Profit
$-1.8M
Net Profit
$-1.7M
Gross Margin
N/A
Operating Margin
-1953.3%
Net Margin
-1853.3%
YoY Growth
531.8%
EPS
$-0.54
Financial Flow
Dermata Therapeutics, Inc. Q3 2023 Financial Summary
Dermata Therapeutics, Inc. reported revenue of $92.8K for Q3 2023, with a net profit of $-1.7M (-1853.3% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $92.8K |
|---|---|
| Net Profit | $-1.7M |
| Gross Margin | N/A |
| Operating Margin | -1953.3% |
| Report Period | Q3 2023 |
Dermata Therapeutics, Inc. Annual Revenue by Year
Dermata Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $63.6K).
| Year | Annual Revenue |
|---|---|
| 2022 | $63.6K |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $-21486 | $85059 | $37540 | $31050 | $92767 |
| YoY Growth | N/A | N/A | -3400.5% | N/A | N/A | N/A | 531.8% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|---|
| Assets | $9.0M | $11.0M | $9.0M | $6.9M | $9.3M | $8.7M | $7.3M |
| Liabilities | $1.2M | $1.4M | $1.5M | $922634 | $1.2M | $682862 | $916817 |
| Equity | $7.9M | $9.7M | $7.5M | $6.0M | $8.1M | $8.0M | $6.4M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-2.6M | $-1.8M | $-2.6M | $-1.8M | $-1.6M | $-1.8M | $-1.8M |